Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2009
04/23/2009WO2009052063A1 Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
04/23/2009WO2009052062A1 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
04/23/2009WO2009052050A1 Dioxolane thymine phosphoramidates as anti-hiv agents
04/23/2009WO2009051992A1 Compositions and methods for treating diseases involving ocular angiogenesis by inhibiting one or more selected receptor tyrosine kinases
04/23/2009WO2009051948A1 Biphenyl carboxylic acids and derivatives thereof
04/23/2009WO2009051922A1 Methods of treating alzheimer's disease with (+) - isopropyl 2-methoxyethyl 4-(2-chloro-3- cyano-phenyl) -1, 4-dihydro-2, 6-dimethyl-pyridine-3, 5-dicarboxylate and a cholinesterase inhibitor
04/23/2009WO2009051910A1 Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
04/23/2009WO2009051909A1 Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
04/23/2009WO2009051908A1 Trans-clomiphene for metabolic syndrome
04/23/2009WO2009051848A1 Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
04/23/2009WO2009051840A2 Compositions and methods for reducing hepatotoxicity associated with drug administration
04/23/2009WO2009051839A1 Aqueous retinoid and benzoyl peroxide gel
04/23/2009WO2009051825A1 Use of rac1 inhibitors to treat kaposi's sarcoma
04/23/2009WO2009051824A2 Combination analgesic employing opioid and neutral antagonist
04/23/2009WO2009051815A1 Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
04/23/2009WO2009051806A2 Modulation of nerve pain activity by resiniferatoxin and uses thereof
04/23/2009WO2009051804A1 Thiazolium compounds for treating or preventing diseases associated with insulin resistance
04/23/2009WO2009051796A2 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents
04/23/2009WO2009051782A1 Deuterated etravirine
04/23/2009WO2009051752A1 Novel lapachone compounds and methods of use thereof
04/23/2009WO2009051747A1 Deuterated lorcaserin
04/23/2009WO2009051746A1 Process for synthesizing phosphonic and phosphinic acid compounds
04/23/2009WO2009051739A1 Methods for protecting the skin from radiation insults
04/23/2009WO2009051718A2 Calcium receptor modulating agents
04/23/2009WO2009051715A1 Quinolizidinone m1 receptor positive allosteric modulators
04/23/2009WO2009051670A2 Oxylipin compounds for the treatment of ophthalmic conditions
04/23/2009WO2009051660A2 Compounds for activating tgf-beta signaling
04/23/2009WO2009051659A2 Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
04/23/2009WO2009051628A2 Transdermal treatment device and method
04/23/2009WO2009051626A1 Cephalosporin derivative formulation
04/23/2009WO2009051618A1 Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
04/23/2009WO2009051580A1 C7-substituted camptothecin analogs
04/23/2009WO2009051578A1 C10-substituted camptothecin analogs
04/23/2009WO2009051556A1 Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)
04/23/2009WO2009051517A1 Pharmaceutical composition in the form of microcapsulated multicomponent particles made of n-carbfmoyl-methyl-4-phenyl-2-pyrrolidone and an auxiliary neutral organic low-molecular component and method for microcapsulation thereof
04/23/2009WO2009051504A1 Benzo- and pyridopyridazinones with analgesic and antiinflammatory activity
04/23/2009WO2009051244A1 Heterocyclic compound
04/23/2009WO2009051223A1 Pharmaceutical composition for treatment of cataract
04/23/2009WO2009051217A1 Fentanyl-containing percutaneous absorption preparation
04/23/2009WO2009051213A1 Therapeutic agent for leukoderma and method for acceleration of pigmentation
04/23/2009WO2009051210A1 Method for producing pyrazole fused ring derivative
04/23/2009WO2009051151A1 Therapeutic agent for trpv1-mediated disease
04/23/2009WO2009051119A1 Pyrimidyl indoline compound
04/23/2009WO2009051112A1 Amide compounds and use of the same
04/23/2009WO2009050898A1 Therapeutic agent for colorectal cancer
04/23/2009WO2009050730A2 Rnai mediated knockdown of numa for cancer therapy
04/23/2009WO2009050726A2 Compositions and methods for improved delivery of bupropion
04/23/2009WO2009050720A1 Pharmaceutical composition of orlistat
04/23/2009WO2009050707A1 Method for inducing hepatocyte proliferation and uses thereof
04/23/2009WO2009050692A2 Platelet-activating factor (paf) analogs and uses thereof
04/23/2009WO2009050580A1 Composition for regulating lipid metabolism
04/23/2009WO2009050575A1 Inhibitors of fungal biofilm-formation
04/23/2009WO2009050555A2 Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof
04/23/2009WO2009050554A2 Pyrazolo [4, 3d] pyrimidine derivatives for use in promoting functional recovery
04/23/2009WO2009050523A1 Azetidinyl g-protein coupled receptor agonists
04/23/2009WO2009050522A1 Azetidinyl g-protein coupled receptor agonists
04/23/2009WO2009050508A2 Separating liquids or liquid and solids and apparatus therefor
04/23/2009WO2009050506A2 Combination 059
04/23/2009WO2009050451A1 Antibacterial composition comprising salvia extracts
04/23/2009WO2009050446A1 Viral therapeutic
04/23/2009WO2009050372A2 Compositions containing lipophosphoramides and use thereof in gene therapy
04/23/2009WO2009050354A1 Isopropanol solvate of rimonabant, preparation method thereof and pharmaceutical compositions containing same
04/23/2009WO2009050353A1 3-methylbutan-1-ol solvate of rimonabant, preparation method thereof and pharmaceutical compositions containing same
04/23/2009WO2009050352A2 Imidazolone derivatives, preparation method thereof and biological use of same
04/23/2009WO2009050348A1 Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same
04/23/2009WO2009050318A1 Pyrazole derivatives of fatty acid amides as ppar-alpha receptor specific activators, preparation method thereof and use of same
04/23/2009WO2009050296A1 Improved antitumoral treatments
04/23/2009WO2009050291A2 Solid dispersion product of n-aryl urea-based drugs
04/23/2009WO2009050289A2 Solid dispersion product containing n-aryl urea-based compound
04/23/2009WO2009050283A1 Compositions for treating multiple sclerosis
04/23/2009WO2009050267A2 Il24 for inducing hyperproliferative or autoimmune cell death
04/23/2009WO2009050258A1 (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
04/23/2009WO2009050253A1 Trisubstituted piperidines
04/23/2009WO2009050252A1 Novel sulfamate compounds for medical use
04/23/2009WO2009050248A1 Substituted piperidino-dihydrothienopyrimidines
04/23/2009WO2009050244A1 Indazoles as glucocorticoid receptor ligands
04/23/2009WO2009050243A1 Indazoles as glucocorticoid receptor ligands
04/23/2009WO2009050242A2 Heterocycle-substituted piperazino-dihydrothienopyrimidines
04/23/2009WO2009050237A1 Cgrp antagonists
04/23/2009WO2009050236A1 Novel piperazino-dihydrothienopyrimidine derivatives
04/23/2009WO2009050235A1 Cgrp antagonists
04/23/2009WO2009050234A1 Cgrp antagonists
04/23/2009WO2009050232A1 Cgrp antagonists
04/23/2009WO2009050228A2 Csf-1r inhibitors for treatment of cancer and bone diseases
04/23/2009WO2009050227A1 Pyridazine derivatives for inhibiting beta amyloid peptide production
04/23/2009WO2009050221A1 Indazoles as glucocorticoid receptor ligands
04/23/2009WO2009050220A1 Indazoles as glucocorticoid receptor ligands
04/23/2009WO2009050218A1 Indazoles as glucocorticoid receptor ligands
04/23/2009WO2009050217A2 Improved pharmaceutical dry powder compositions for inhalation
04/23/2009WO2009050204A1 Quinoline derivatives used to treat inflammatory and allergic diseases
04/23/2009WO2009050201A2 4-phenyl-5-oxo-imidazole derivatives, pharmaceutical compositions and uses therof
04/23/2009WO2009050200A1 Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators
04/23/2009WO2009050199A1 Purine derivatives as adenosine al receptor ligands
04/23/2009WO2009050198A2 Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases
04/23/2009WO2009050197A2 Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
04/23/2009WO2009050186A1 Trisubstituted 1,2,4-triazoles
04/23/2009WO2009050185A1 1,3,5-trisubstituted triazole derivative
04/23/2009WO2009050183A2 Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors
04/23/2009WO2009050159A1 Combination of fluticasone furoate with 4- [ (4-chl0r0phenyl)methyl] -2- ({ (2r)-i- [4-(4-{ [3-(hexahydr0-lh-azepin-l-yl) propyl ] oxy} phenyl) butyl] -2-pyrrolidinyl}methyl) -1 (2h) - phthalaz inone
04/23/2009WO2009050143A1 Combinations of (1r, 2r, 3s, 4s) -n4- (3-aminocarbonylbicyclo [2. 2. 1] hept-5-ene-2-yl) - 5-fluoro-n2- [ ( 3 - methyl-4- (4 -methylpiperazin-1-yl] phenyl-2, 4-pyrimidineamine